Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 Patients

Overview

Journal Future Microbiol

Specialties Infectious Diseases
Microbiology

Date 2021 Jan 6

PMID 33404263

Citations 22

Authors

Reza Ghanbari

Ali Teimoori

Anahita Sadeghi

Ashraf Mohamadkhani

Sama Rezasoltani

Ebrahim Asadi

Abolghasem Jouyban

Susan Cj Sumner

Affiliations

Soon will be listed here.

Abstract

COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients.

Citing Articles

Study of different heterocycles showing significant anti-severe acute respiratory syndrome 2 activity and .

Yengoyan A, Gomktsyan T, Pivazyan V, Ghazaryan E, Shainova R, Karapetyan A Vet World. 2024; 17(6):1281-1290.

PMID: 39077461 PMC: 11283614. DOI: 10.14202/vetworld.2024.1281-1290.

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.

Kumawat P, Agarwal L, Sharma K Curr Microbiol. 2024; 81(7):169.

PMID: 38733424 DOI: 10.1007/s00284-024-03671-3.

Prevalence and association of oral manifestations with disease severity in patients diagnosed with COVID‑19: A cross‑sectional study.

Campeanu A, Rus M, Ispas S, Herlo A, Craciun A, Ionescu C Med Int (Lond). 2024; 4(3):30.

PMID: 38660127 PMC: 11040283. DOI: 10.3892/mi.2024.154.

Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of studies.

Mehyar N J Virus Erad. 2023; 9(2):100327.

PMID: 37363132 PMC: 10214743. DOI: 10.1016/j.jve.2023.100327.

Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.

Sayan M, Arikan A, Sanlidag E Viruses. 2023; 15(5).

PMID: 37243152 PMC: 10223230. DOI: 10.3390/v15051066.

References

Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y . Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. J Clin Transl Hepatol. 2019; 7(3):221-225. PMC: 6783684. DOI: 10.14218/JCTH.2019.00018. View

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Yoshimoto F . The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020; 39(3):198-216. PMC: 7245191. DOI: 10.1007/s10930-020-09901-4. View

Zhang H, Penninger J, Li Y, Zhong N, Slutsky A . Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586-590. PMC: 7079879. DOI: 10.1007/s00134-020-05985-9. View

Morse J, Lalonde T, Xu S, Liu W . Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem. 2020; 21(5):730-738. PMC: 7162020. DOI: 10.1002/cbic.202000047. View

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P . Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020; 27(3):325-328. PMC: 7154514. DOI: 10.1016/j.chom.2020.02.001. View

Calligari P, Bobone S, Ricci G, Bocedi A . Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs. Viruses. 2020; 12(4). PMC: 7232184. DOI: 10.3390/v12040445. View

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L . Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11(1):1620. PMC: 7100515. DOI: 10.1038/s41467-020-15562-9. View

10.

Hui D, Azhar E, Madani T, Ntoumi F, Kock R, Dar O . The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-266. PMC: 7128332. DOI: 10.1016/j.ijid.2020.01.009. View

11.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

12.

Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C . Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect. 2020; 8(6):e00674. PMC: 7596664. DOI: 10.1002/prp2.674. View

13.

Chandwani A, Shuter J . Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2009; 4(5):1023-33. PMC: 2621403. DOI: 10.2147/tcrm.s3285. View

14.

Yu R, Chen L, Lan R, Shen R, Li P . Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents. 2020; 56(2):106012. PMC: 7205718. DOI: 10.1016/j.ijantimicag.2020.106012. View

15.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

17.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

18.

OKeefe B, Giomarelli B, Barnard D, Shenoy S, Chan P, McMahon J . Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2009; 84(5):2511-21. PMC: 2820936. DOI: 10.1128/JVI.02322-09. View

19.

Lee Y, Duh Y, Wang S, Lai M, Yuan H, Lim C . Using an Old Drug to Target a New Drug Site: Application of Disulfiram to Target the Zn-Site in HCV NS5A Protein. J Am Chem Soc. 2016; 138(11):3856-62. DOI: 10.1021/jacs.6b00299. View

20.

Kumar S, Zhi K, Mukherji A, Gerth K . Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. Viruses. 2020; 12(5). PMC: 7290948. DOI: 10.3390/v12050486. View